A Mitochondria-Targeted Iridium(iii)-Based Photoacid Generator Induces Dual-Mode Photodynamic Damage Within Cancer Cells

Liang He,Ming-Fang Zhang,Zheng-Yin Pan,Kang-Nan Wang,Zi-Jian Zhao,Yi Li,Zong-Wan Mao

DOI: https://doi.org/10.1039/c9cc04871e

IF: 4.9

2019-01-01

Chemical Communications

Abstract:An Ir(iii)-based photoacid generator was developed as a dual-mode photodynamic therapy agent to kill cancer cells under hypoxic conditions.

What problem does this paper attempt to address?

Photodecaging of a Mitochondria-Localized Iridium(III) Endoperoxide Complex for Two-Photon Photoactivated Therapy under Hypoxia

Shi Kuang,Fangmian Wei,Johannes Karges,Libing Ke,Kai Xiong,Xinxing Liao,Gilles Gasser,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1021/jacs.1c13137

IF: 15

2022-01-01

Journal of the American Chemical Society

Abstract:Despite the clinical success of photodynamic therapy (PDT), the application of this medical technique is intrinsically limited by the low oxygen concentrations found in cancer tumors, hampering the production of therapeutically necessary singlet oxygen (O-1(2)). To overcome this limitation, we report on a novel mitochondria-localized iridium(III) endoperoxide prodrug (2-O-IrAn), which, upon two-photon irradiation in NIR, synergistically releases a highly cytotoxic iridium(III) complex (2-IrAn), singlet oxygen, and an alkoxy radical. 2-O-IrAn was found to be highly (photo-)toxic in hypoxic tumor cells and multicellular tumor spheroids (MCTS) in the nanomolar range. To provide cancer selectivity and improve the pharmacological properties of 2-O-IrAn, it was encapsulated into a biotinfunctionalized polymer. The generated nanoparticles were found to nearly fully eradicate the tumor inside a mouse model within a single treatment. This study presents, to the best of our knowledge, the first example of an iridium(III)-based endoperoxide prodrug for synergistic photodynamic therapy/photoactivated chemotherapy, opening up new avenues for the treatment of hypoxic tumors.
Unusual Electron Donor-Acceptor Sequenced NIR AIEgen for Highly Efficient Mitochondria-Targeted Cancer Cell Photodynamic Therapy.

Kaiwu Yu,Jiayue Pan,Mei Tian,Haoke Zhang,Chentao Jin,Hong Zhang,Zhengwei Mao,Qinggang He

DOI: https://doi.org/10.1002/asia.202200571

2022-01-01

Chemistry - An Asian Journal

Abstract:Photodynamic therapy (PDT) is recognized to be a promising strategy for anticancer treatment. Considering the progressive application of PDT in clinical trials, highly efficient and photostable photosensitizers (PSs) are in strong demand. Aggregation-induced emission (AIE) based PSs are promising phototheranostic materials for tumor imaging and PDT due to their high fluorescence efficiency and photostability. Herein, a mitochondria-targeted PS, TPA-2TCP with AIE characteristics is developed by adopting an acceptor-π-donor-π-acceptor (A-π-D-π-A) structure. The untypical sequence of the electron donors and electron acceptors endows the derived AIE PS with evident redshift of the absorption and emission, and efficient generation of reactive oxygen species. With the positively charged pyridinium groups, nanoparticulated AIE PS (TPA-2TCP NPs) exhibits high cell binding efficiency towards 4T1 breast cancer cells, leading to the massive cell death via the apoptotic pathway under white light irradiation, demonstrating its potential application in cancer imaging and PDT.
A Mitochondria‐Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects under Hypoxia

Wen Lv,Zhang,Kenneth Yin Zhang,Huiran Yang,Shujuan Liu,Aqiang Xu,Song Guo,Qiang Zhao,Wei Huang

DOI: https://doi.org/10.1002/anie.201604130

2016-01-01

Angewandte Chemie

Abstract:Organelle-targeted photosensitizers have been reported to be effective photodynamic therapy (PDT) agents. In this work, we designed and synthesized two iridium(III) complexes that specifically stain the mitochondria and lysosomes of living cells, respectively. Both complexes exhibited long-lived phosphorescence, which is sensitive to oxygen quenching. The photocytotoxicity of the complexes was evaluated under normoxic and hypoxic conditions. The results showed that HeLa cells treated with the mitochondria-targeted complex maintained a slower respiration rate, leading to a higher intracellular oxygen level under hypoxia. As a result, this complex exhibited an improved PDT effect compared to the lysosome-targeted complex, especially under hypoxia conditions, suggestive of a higher practicable potential of mitochondria-targeted PDT agents in cancer therapy.
Mitochondria-localized Iridium(iii) Complexes with Anthraquinone Groups As Effective Photosensitizers for Photodynamic Therapy under Hypoxia

Song Guo,Meiping Han,Ruizhe Chen,Yanling Zhuang,Liang Zou,Shujuan Liu,Wei Huang,Qiang Zhao

DOI: https://doi.org/10.1007/s11426-019-9583-4

2019-01-01

Science China Chemistry

Abstract:Photodynamic therapy (PDT) is a potential way for the tumor treatment. However, it notably suffers the limitation of hypoxia in solid tumors. Thus, it is significant to develop effective photosensitizers which can exhibit excellent therapeutic performance under both normoxia and hypoxia. Herein, we reported four ionic iridium(III) complexes ( Ir1 – Ir4 ) with anthraquinone groups which can regulate their excited state energy levels effectively. Among them, the energy gap of Ir1 was between 1.63 and 2.21 eV, which can match well with that of O 2 , and the HOMO energy of Ir1 is less than −5.51 eV. Compared with Ir2 – Ir4 , the luminescent quantum efficiency of Ir1 was the highest. Particularly, Ir1 can specifically target the mitochondria of the tumor cells. Meanwhile, Ir1 showed high singlet oxygen quantum yields ( Φ Δ ) in both solutions and living cells with low cytotoxicity. The results of PDT experiments revealed that Ir1 , as a photosensitizer, exhibited excellent therapeutic effect not only in normoxia but also in hypoxia condition. We believe that this work is meaningful for developing excellent PDT agents based on cyclometalated Ir(III) complexes via rational ligand modification.
Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Yi Li,Kang-Nan Wang,Liang He,Liang-Nian Ji,Zong-Wan Mao

DOI: https://doi.org/10.1016/j.jinorgbio.2019.110976

IF: 4.336

2019-01-01

Journal of Inorganic Biochemistry

Abstract:Metal N-Heterocyclic carbene (NHC) complexes are expected to be new opportunities for the development of anticancer metallodrugs. In this work, two near-infrared (NIR) emitting iridium(III)-NHC complexes Ir1 and Ir2 have been explored as mitochondria-targeted anticancer and photodynamic agents. These complexes are more cytotoxic than cisplatin against the cancer cells screened, and display higher cytotoxicity in the presence of 450 nm and 630 nm LED light. Colocalization and quantitative studies indicated that these complexes could specially localize to mitochondria. Mechanism studies show that these complexes increase intracellular reactive oxygen species (ROS) level, reduce mitochondrial membrane potential (MMP) and induce some degree of early apoptosis. Further studies found that Ir1could induce mitophagy at dark and necrocytosis under the irradiation of 630 nm LED light. The in vitro and in vivo photoxicity studies revealed that Ir1 is a promising photodynamic therapy (PDT) agent and could significantly inhibit tumor growth.
Cyclometalated Iridium(iii) Complexes for Mitochondria-Targeted Combined Chemo-Photodynamic Therapy.

Wei-Wei Qin,Zheng-Yin Pan,Dai-Hong Cai,Yi Li,Liang He

DOI: https://doi.org/10.1039/d0dt00180e

IF: 4

2020-01-01

Dalton Transactions

Abstract:The potency of two anticancer iridium-based molecular compounds was greatly enhanced under light irradiation.
Cyclometalated iridium(III) tetrazine complexes for mitochondria-targeted two-photon photodynamic therapy

Zanru Tan,Mingwei Lin,Jiangping Liu,Huihui Wu,Hui Chao

DOI: https://doi.org/10.1039/d4dt01665c

IF: 4

2024-07-13

Dalton Transactions

Abstract:The fast-moving field of photodynamic therapy (PDT) has provided fresh opportunities to expand the potential of metallodrugs to combat cancers in a light-controlled manner. As such, in the present study, a series of cyclometalated Ir(III) complexes modified with tetrazine functional group (namely Ir-ppy-Tz, Ir-pbt-Tz, Ir-dfppy-Tz) are developed as potential two-photon photodynamic anticancer agents. These complexes target mitochondria but exhibit low toxicity towards HLF primary lung fibroblast normal cells in the dark. When receiving a low-dose one- or two-photon PDT, they become highly potent towards A549 lung cancer cells (IC50 values ranging from 24.0 nM to 96.0 nM) through the generation of reactive oxygen species (ROS) to induce mitochondrial damage and subsequent apoptosis. Our results indicated that the incorporation of tetrazine with cyclometalated Ir(III) matrices would increase the singlet oxygen (1O2) quantum yield (ΦΔ) and, meanwhile, enable a type I PDT mechanism. Ir-pbt-Tz, with an utmost two-photon absorption (TPA) cross-section (σ2 = 102 GM), shows great promise in serving as a two-photon PDT agent for phototherapy.

chemistry, inorganic & nuclear
Mitochondria-targeted and Photo-Activated CO Release for Synergistic Photodynamic Therapy

Xin Li,Yuan Liu,Qiao Hu,Tiancong Shi,Jingwei Pan,Saran Long,Wen Sun,Jiangli Fan,Jianjun Du,Xiaojun Peng

DOI: https://doi.org/10.1016/j.snb.2024.136357

2024-01-01

Abstract:In photodynamic therapy, organelle-targeted strategies are allowed to selectively impair specific cell functions, leading to efficiently eliminating cancer cells. Carbon monoxide (CO), as a highly toxic gaseous signaling molecule, often plays an active role in enhancing the sensitivity of cancer cells during cancer treatment, making cells prone to apoptosis. Therefore, we report a photosensitizer Cy-Mn, which possesses the capability of photoactivatable CO releasing and 1O2 generation. Furthermore, during the treatment, Cy-Mn has perfect synergistic effect on the cancer cells for enhanced photodynamic therapy. Under 760nm laser irradiation, Cy-Mn released manganese ions, which altered the permeability transition pore of the mitochondria membrane, reduced the mitochondrial membrane potential, and exhibited severe phototoxicity. Additionally, we investigated the imaging of Cy-Mn in vivo, and found Cy-Mn displayed excellent fluorescence imaging capabilities, which further promotes its biological applications in imaging-guided PDT.
Mitochondria-targeted cyclometalated iridium (III) complex for H2S-responsive intracellular redox regulation as potent photo-oxidation anticancer agent

Ben Liu,Xu Huang,Meng Hu,Zhiyin Chen,Wei Zhang,Yi Li

DOI: https://doi.org/10.1007/s00775-022-01957-0

2022-09-06

Abstract:Owing to the safety and low toxicity, photodynamic therapy (PDT) for cancer treatment has received extensive attention. However, the excess H 2 S in cancer cells reduces the PDT efficiency, because H 2 S indirectly depletes the reactive oxygen species (ROS). To improve anticancer efficiency, a mitochondria-targeted iridium(III) complex Ir-MMB has been developed as H 2 S consumer and photo-oxidation anticancer agent. On the one hand, complex Ir-MMB can consume H 2 S with sensitive phosphorescence turn-on, which has been successfully applied to exogenous and endogenous H 2 S response imaging in living cells. On the other hand, Ir-MMB can enhance its anticancer activity and cause photo-oxidation damage via catalyzing the oxidation of reduced form of nicotinamide-adenine dinucleotide (NADH) to NAD + and producing H 2 O 2 under light, and ultimately results in cell apoptosis through mitochondrial depolarization and ROS production.

chemistry, inorganic & nuclear,biochemistry & molecular biology
A Mitochondria-Localized Iridium(III)-Chlorin E6 Conjugate for Synergistic Sonodynamic and Two-Photon Photodynamic Therapy Against Melanoma

Zhuoli Chen,Tao Feng,Johannes Karges,Chengzhi Jin,Yukun Zhao,Liangnian Ji,Hui Chao,shen jinchao

DOI: https://doi.org/10.1039/d2qi00635a

IF: 7.779

2022-01-01

Inorganic Chemistry Frontiers

Abstract:While melanoma in its early stages can be successfully treated, the prognosis strongly worsens with an increasing depth of the tumor. Capitalizing on this, there is an urgent need for...

chemistry, inorganic & nuclear
Two-photon Photodynamic Ablation of Tumor Cells by Mitochondria-Targeted Iridium(iii) Complexes in Aggregate States.

Kangqiang Qiu,Miao Ouyang,Yukang Liu,Huaiyi Huang,Chaofeng Liu,Yu Chen,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1039/c7tb00731k

IF: 7.571

2017-01-01

Journal of Materials Chemistry B

Abstract:Two iridium(iii) complexes with a rotary phenyl substituent ligand were used as mitochondria-targeted photosensitizers for two-photon photodynamic therapy in aggregate states.
A Mitochondria-Targeting Dinuclear Ir-Ru Complex As a Synergistic Photoactivated Chemotherapy and Photodynamic Therapy Agent Against Cisplatin-Resistant Tumour Cells.

Cheng Zhang,Ruilin Guan,Xinxing Liao,Cheng Ouyang,Thomas W. Rees,Jiangping Liu,Yu Chen,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1039/c9cc05998a

IF: 4.9

2019-01-01

Chemical Communications

Abstract:A mitochondria-targeting hetero-binuclear Ir(iii)-Ru(ii) complex was developed as a photoactivated chemotherapy (PACT) and photodynamic therapy (PDT) bifunctional agent to achieve a synergistic effective therapeutic outcome for the therapy of cisplatin-resistant tumour cells.
A Mitochondrion-Targeted BODIPY-Ir(III) Conjugate As a Photoinduced ROS Generator for the Oxidative Destruction of Triple-Negative Breast Cancer Cells.

Liping Qiao,Jiangping Liu,Shi Kuang,Xinxing Liao,Junfeng Kou,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1039/d1dt01460a

IF: 4

2021-01-01

Dalton Transactions

Abstract:Photodynamic therapy (PDT) provides an alternative option to root out localized triple-negative breast cancer (TNBC) and has been experiencing a surge of research interest over recent years. In this study, we put forward a paradigm of designing novel transition metal-based PSs with the following characteristics: favorable cell-permeability, significant light-harvesting ability and prominent ROS yield. A novel BODIPY-Ir(III) conjugate has been designed as a photoinduced ROS (1O2, ˙OH and ˙O2-) generator. BODIPY-Ir is highly photoactive in subduing cancer cells in the PDT regimen with PI values ranging from 172 to 519 and EC50 in the nanomolar regime. Among various cancerous cell lines, TNBC was especially sensitive to BODIPY-Ir-mediated PDT, with a stunning EC50 value of 4.32 nM (PI = 519) under a moderate flux of visible-light irradiation (500 nm, 10.5 mW cm-2). BODIPY-Ir mainly accumulates in mitochondria and induces cell apoptosis under irradiation. Furthermore, the nanomolar antiproliferative activity of BODIPY-Ir is retained under hypoxia (2.5% O2). This work sheds light on instilling the O2-independent type I mechanism and conferring a red-shift absorption to metal-based PSs which fundamentally facilitate the clinical translation of PSs.
Photosensitizers with Aggregation-Induced Emission for Mitochondrion-Targeting Photodynamic Therapy

Lingxiang Guo,Juping Li,Zhiyang Liu,Quan Li

DOI: https://doi.org/10.7536/PC220335

2022-01-01

Abstract:Photodynamic therapy is a safe and noninvasive treatment method based on photosensitizers and light. It has broad application prospects in cancer treatment and sterilization. Photosensitizers react with oxygen under light excitation to produce reactive oxygen species with high reactivity. Excessive reactive oxygen species in cells can oxidize and damage cellular components such as proteins, nucleic acids and lipids, and induce cell apoptosis or necrosis. The emerging photosensitizers with aggregation-induced emission (AIE) characteristics can emit strong fluorescence under light excitation in the aggregate state, and efficiently produce reactive oxygen species at the same time, which solves the problem of fluorescence quenching of traditional photosensitizers in the aggregate state. AIE photosensitizers are easy to realize image-guided photodynamic therapy, which has attracted much attention in recent years. Mitochondria, as cell energy factories, are rich in oxygen and are ideal targets for photodynamic therapy. Mitochondria are more numerous in cancer cells and play an important role in both tumorization and programmed cell death. Currently, the AIE photosensitizers targeting the mitochondria of cancer cells are mainly cationic compounds, including pyridium ions, quinolinium ions, isoquinolinium ions and triphenylphosphenonium ions. This review summarizes the molecular types and design strategies of AIE photosensitizers targeting the mitochondria of cancer cells, as well as their applications in photodynamic therapy of tumors.
Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Miao Ouyang,Leli Zeng,Kangqiang Qiu,Yu Chen,Liang-Nian Ji,Hui Chao

DOI: https://doi.org/10.1002/ejic.201601129

IF: 2.551

2017-01-01

European Journal of Inorganic Chemistry

Abstract:Photodynamic therapy (PDT) is an attractive therapeutic modality with high therapeutic efficacy and less side effects compared with other therapies. Herein, we developed a series of cyclometalated Ir-III complexes based on 2,2'-biimidazole with different alkyl substitutions (methyl, ethyl, propyl, and butyl). These complexes can efficiently produce singlet oxygen upon light irradiation. In vitro photocytotoxicity towards four cell lines (HeLa, A549, A549R, and LO2) was examined. Ir1-Ir5 show quick penetration of cells, remarkable mitochondrial accumulation, strong phototoxicity, and they exhibit high selectivity between tumor cells and normal cells. With the highest O-1(2) quantum yields, Ir5 presents the best PDT efficiency with a high phototoxicity index (PI) value (PI = 150) towards HeLa cells. This work provides a valuable avenue to improve the PDT effect by tuning the lipophilicity and other properties with variation of the alkyl substitution on the photosensitizer. In addition, their satisfying PDT effect to a cisplatin-resistant cell line (A549R) may contribute to the future development of improved chemotherapeutics.
Selectively Lighting Up Two-Photon Photodynamic Activity in Mitochondria with Aie-Active Iridium(Iii) Complexes

Jiangping Liu,Chengzhi Jin,Bo Yuan,Xingguo Liu,Yu Chen,Liangnian Ji,Hui Chao

DOI: https://doi.org/10.1039/c6cc10015e

IF: 4.9

2017-01-01

Chemical Communications

Abstract:Herein a series of mitochondria-targeted AIE (aggregation-induced emission)-active Ir(III) complexes were designed to selectively exert one-/two-photon photodynamic activities in mitochondria to address the issues which current PDT are confronted with (i.e., shallow penetration depth of routinely used irradiation; systematic toxicity associated with effective drug concentration; concentration-quenched photodynamic activity at the target, etc.).
Mitochondrial‐DNA‐Targeted IrIII‐Containing Metallohelices with Tunable Photodynamic Therapy Efficacy in Cancer Cells

Xuezhao Li,Jinguo Wu,Lei Wang,Cheng He,Liyong Chen,Yang Jiao,Chunying Duan

DOI: https://doi.org/10.1002/anie.201915281

2020-01-01

Angewandte Chemie

Abstract:The development of DNA-targeted photodynamic therapy (PDT) agents for cancer treatment has drawn substantial attention. Herein, the design and synthesis of dinuclear Ir-III-containing luminescent metallohelices with tunable PDT efficacy that target mitochondrial DNA in cancer cells are reported. The metallohelices are fabricated using dynamic imine-coupling chemistry between aldehyde end-capped fac-Ir(ppy)(3) handles and linear alkanediamine spacers, followed by reduction of the imine linkages. The length and odd-even character of the diamine alkyl linker determined the stereochemistry (helicates vs. mesocates). Compared to the helicates, the mesocates exhibit improved apoptosis-induction upon white-light irradiation. Molecular docking studies indicate that the mesocate with a proper length of diamine spacers shows stronger affinity for the minor groove of DNA. This study highlights the potential of DNA-targeting Ir-III-containing metallohelices as PDT agents.
Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy

Huan Lu,Xinpeng Jiang,Yanyan Chen,Ke Peng,Yiming Huang,Hao Zhao,Qi Chen,Fengting Lv,Libing Liu,Shu Wang,Yuguo Ma

DOI: https://doi.org/10.1039/d0nr03398g

IF: 6.7

2020-01-01

Nanoscale

Abstract:Cyclometalated Ir(iii) complexes, with a long triplet state lifetime and good photophysical properties, are good candidates for simultaneous imaging and photodynamic therapy (PDT). Herein, we synthesize a cyclometalated Ir(iii) complex, Ir(tiq)(2)ppy, whose triplet excited state lifetime is 2.9 mu s and singlet oxygen generation quantum yield is approximately 100% (compared to tetraphenylporphyrin). Ir(tiq)(2)ppy nanoparticles (Ir(tiq)(2)ppy NPs) are prepared to achieve water solubility and mitochondria-targeting ability by co-precipitating with polystyrene grafted with carboxyl-terminated poly(ethylene glycol) (PS-PEG). Ir(tiq)(2)ppy NPs have higher PDT efficiency than Ir(tiq)(2)ppy at concentrations as low as 1.6 mu g mL(-1)for MCF-7 breast cancer cells under white light irradiation at quite low light intensity (5 mW cm(-2)). Besides, it is worth noting that the emission quenching of Ir(tiq)(2)ppy in aqueous solution has been conquered by using Ir(tiq)(2)ppy NPs, thus the distribution of the therapeutic agents in mitochondria can be tracked by confocal laser scanning microscopy (CLSM). The mechanism of killing cancer cells under irradiation is investigated, and the results indicate that cell death is caused by mitochondria-mediated apoptosis, which is induced by the ROS generated under light irradiation.
Biotin-modified Cyclometalated Iridium-Based Photosensitizers As Mitochondria-Targeted Theranostic Agents for Tumor Photodynamic Therapy in Vitro and in Vivo

Lai Wei,Xiangdong He,Xinyue Shang,Martha Kandawa-Shultz,Guoqiang Shao,Yihong Wang

DOI: https://doi.org/10.1016/j.dyepig.2023.111641

IF: 5.122

2023-01-01

Dyes and Pigments

Abstract:Photodynamic therapy (PDT) is a promising non-invasive treatment technique for various types of cancer. Photoluminescent cyclometalated Ir(III) complexes, a distinctive genre of photosensitizers (PSS), have garnered significant interest due to their exceptional selective toxicity towards cancerous cells and minimal cytotoxicity towards normal cells. This study aimed to investigate the application of three newly designed biotin-modified cyclometalated Ir(III) complexes (Ir1-Ir3) for the treatment of cancer. The three complexes were found to have good photocatalytic activity, with singlet oxygen (O-1(2)) yields ranging from 0.24 to 0.65 in aqueous solutions. The results suggest that these complexes have the potential as phototherapeutic and photodiagnostic agents for cancer treatment. Additionally, the biotin fragments in the Ir1-Ir3 structures enable their selective targeting of tumor cells. Notably, Ir3 displayed negligible dark toxicity towards A549 human lung cancer cells (IC50 > 100 mu M), but its value decreased to 0.25 mu M after 15 min of 425 nm (40 mW/cm(2)) light exposure. Furthermore, these complexes exhibited low phototoxicity towards non-cancerous BHK mouse kidney cells. Further investigation demonstrated that Ir3 had potent targeting abilities for mitochondria, and could trigger cell apoptosis through the activation of ROS-mediated mitochondrial signaling pathways under 425 nm light irradiation. In vivo studies revealed that Ir3 effectively suppressed tumor growth in A549 xenograft-bearing mice when exposed to 425 nm light. These results indicate that Ir3 has the potential to be a valuable photosensitizer drug for the photodynamic treatment of tumors.
Long-wavelength triggered iridium(III) complex nanoparticles for photodynamic therapy against hypoxic cancer

Shengnan Liu,Ziwei Wang,Zihan Wu,Haoran Chen,Dongxia Zhu,Gungzhe Li,Mingming Yan,Martin R Bryce,Yulei Chang

DOI: https://doi.org/10.1039/d4cc03501a

2024-08-22

Abstract:A long-wavelength triggered cationic iridium(III) complex, Ir5, and its corresponding nanoparticles with the ability to generate type I and type II reactive oxygen species have been synthesised. The complex targets mitochondria and achieves an excellent photodynamic therapy effect in hypoxic cancer cells.

A Mitochondria-Targeted Iridium(iii)-Based Photoacid Generator Induces Dual-Mode Photodynamic Damage Within Cancer Cells

Photodecaging of a Mitochondria-Localized Iridium(III) Endoperoxide Complex for Two-Photon Photoactivated Therapy under Hypoxia

Unusual Electron Donor-Acceptor Sequenced NIR AIEgen for Highly Efficient Mitochondria-Targeted Cancer Cell Photodynamic Therapy.

A Mitochondria‐Targeted Photosensitizer Showing Improved Photodynamic Therapy Effects under Hypoxia

Mitochondria-localized Iridium(iii) Complexes with Anthraquinone Groups As Effective Photosensitizers for Photodynamic Therapy under Hypoxia

Synthesis, Photophysical and Anticancer Properties of Mitochondria-Targeted Phosphorescent Cyclometalated Iridium(iii) N-heterocyclic Carbene Complexes.

Cyclometalated Iridium(iii) Complexes for Mitochondria-Targeted Combined Chemo-Photodynamic Therapy.

Cyclometalated iridium(III) tetrazine complexes for mitochondria-targeted two-photon photodynamic therapy

Mitochondria-targeted and Photo-Activated CO Release for Synergistic Photodynamic Therapy

Mitochondria-targeted cyclometalated iridium (III) complex for H2S-responsive intracellular redox regulation as potent photo-oxidation anticancer agent

A Mitochondria-Localized Iridium(III)-Chlorin E6 Conjugate for Synergistic Sonodynamic and Two-Photon Photodynamic Therapy Against Melanoma

Two-photon Photodynamic Ablation of Tumor Cells by Mitochondria-Targeted Iridium(iii) Complexes in Aggregate States.

A Mitochondria-Targeting Dinuclear Ir-Ru Complex As a Synergistic Photoactivated Chemotherapy and Photodynamic Therapy Agent Against Cisplatin-Resistant Tumour Cells.

A Mitochondrion-Targeted BODIPY-Ir(III) Conjugate As a Photoinduced ROS Generator for the Oxidative Destruction of Triple-Negative Breast Cancer Cells.

Photosensitizers with Aggregation-Induced Emission for Mitochondrion-Targeting Photodynamic Therapy

Cyclometalated Ir(III) Complexes as Mitochondria-Targeted Photodynamic Anticancer Agents

Selectively Lighting Up Two-Photon Photodynamic Activity in Mitochondria with Aie-Active Iridium(Iii) Complexes

Mitochondrial‐DNA‐Targeted IrIII‐Containing Metallohelices with Tunable Photodynamic Therapy Efficacy in Cancer Cells

Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy

Biotin-modified Cyclometalated Iridium-Based Photosensitizers As Mitochondria-Targeted Theranostic Agents for Tumor Photodynamic Therapy in Vitro and in Vivo

Long-wavelength triggered iridium(III) complex nanoparticles for photodynamic therapy against hypoxic cancer